Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12016140 | PMC |
| http://dx.doi.org/10.1186/s13098-025-01703-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
GLP-1 receptor agonists: emerging therapeutic potential in psoriasis management - current evidence and future outlook.
Eur J Clin Pharmacol
August 2025
Dr. Kiran C. Patel College of Osteopathic Medicine, Nova Southeastern University, Tampa Bay Regional Campus, Clearwater, FL, USA.
Background: Psoriasis is a chronic inflammatory skin disease driven by immune dysregulation and often exacerbated by metabolic comorbidities. Glucagon-like peptide-1 receptor agonists (GLP-1RAs), initially developed for type 2 diabetes mellitus (T2DM) and weight management, have emerged as a promising treatment due to their anti-inflammatory and immunomodulatory properties.
Purpose: This review evaluates the clinical efficacy, mechanisms of action, and limitations of GLP-1RAs, such as liraglutide, exenatide, and semaglutide, in the management of psoriasis.
Non-Arteritic Anterior Ischemic Optic Neuropathy in an Otherwise Healthy Young Adult Patient Treated with Liraglutide and Semaglutide for Weight Loss: A Cautionary Tale.
Int Med Case Rep J
August 2025
Eye Clinic, Department of Surgical Sciences, University of Cagliari, Cagliari, 09124, Italy.
Purpose: To report a case of non-arteritic ischemic optic neuropathy (NAION) in an otherwise healthy patient treated with Glucagon-Like Peptide-1 (GLP-1) receptor agonists (RAs) liraglutide and semaglutide.
Observations: A 47-year-old Caucasian female with a Body Mass Index (BMI) of 27.92, and no known history of diabetes, hypertension, or ischemic heart disease, developed a progressive decline in visual acuity in the right eye one month after initiating liraglutide therapy for weight loss.
[Rapid weight loss through GLP-1 receptor agonists as lifestyle phenomenon and implications for plastic esthetic medicine].
HNO
August 2025
Klinik für Hals-Nasen-Ohren-Heilkunde, plastische Gesichtschirurgie, Kreiskrankenhaus Gummersbach, Klinikum Oberberg, Wilhelm-Breckow-Allee 20, 51643, Gummersbach, Deutschland.
Background: Glucagon-like peptide‑1 receptor agonists (GLP‑1 RA), such as semaglutide and tirzepatide were originally developed for treatment of type 2 diabetes and have shown significant weight loss effects. This has led to increasing off-label use for esthetic weight reduction. The associated facial changes, particularly volume loss, skin laxity and increased wrinkle formation, are gaining attention in plastic esthetic medicine.
View Article and Find Full Text PDFGeneralizability of glucagon-like peptide 1 receptor agonist clinical trial results to product labeling and the real world.
Ann N Y Acad Sci
August 2025
Epidemiology Unit, Health Research Institute-Fundación Jiménez Díaz University Hospital, Universidad Autónoma de Madrid, Madrid, Spain.
"Generalizability" refers to when trial results are applied to populations that did not participate in the trial. It is important when pre-licensing trial results are used by regulators to authorize the use of a drug in different countries. To "generalize" the results, the trial sample must represent the population from which participants are drawn.
View Article and Find Full Text PDFComparative ocular outcomes of tirzepatide versus other anti-obesity medications in people with obesity.
Commun Med (Lond)
August 2025
Department of Pediatrics, Chung Shan Medical University Hospital, Taichung, Taiwan.
Background: Obesity affects over one billion people worldwide and is associated with ocular complications, yet comparative effects of newer anti-obesity medications on eye health remain poorly understood. We examine ocular health outcomes among individuals with obesity receiving Tirzepatide, Semaglutide, Phentermine/Topiramate, Naltrexone/Bupropion, or Phentermine monotherapy.
Methods: This propensity-score matched cohort study analyzed TriNetX US network data from November 2023 through April 2025.